377 assets in Pancreatic Neoplasm

Therapeutic assets addressing Pancreatic Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Tinzaparin Pancreatic Neoplasm	Helsinki University Central Hospital	P4	BBB (72)
Oxaliplatin Pancreatic Neoplasm	Memorial Sloan Kettering Cancer Center	P3	BB (68)
Cis-Diamminedichloroplatinum Ii Pancreatic Neoplasm	Taiho Oncology, Inc.	P3	BB (67)
Fluorouracilum Pancreatic Neoplasm	Memorial Sloan Kettering Cancer Center	P3	BB (67)
Capecitabine Pancreatic Neoplasm	Tianjin Medical University Cancer Institute and Hospital	P3	BB (66)
Irinotecan Pancreatic Neoplasm	Memorial Sloan Kettering Cancer Center	P3	BB (66)
Desflurane Pancreatic Neoplasm	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	P4	BB (65)
Nivolumab Pancreatic Neoplasm	Orion Corporation, Orion Pharma	P2	B (63)
S-1 Pancreatic Neoplasm	Ruijin Hospital	P4	B (62)
Tislelizumab Pancreatic Neoplasm	Memorial Sloan Kettering Cancer Center	P2	B (62)
Cyclophosphamide Pancreatic Neoplasm	National Cancer Institute (NCI)	P4	B (61)
Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer Pancreatic Neoplasm	Tianjin Medical University Cancer Institute and Hospital	P3	B (61)
Cetuximab Pancreatic Neoplasm	Revolution Medicines, Inc.	P3	B (60)
Dexasone Pancreatic Neoplasm	Takeda	P4	B (60)
Docetaxel Pancreatic Neoplasm	Hummingbird Bioscience	P2	B (60)
Epirubicin Pancreatic Neoplasm	Cambridge University Hospitals NHS Foundation Trust	P4	B (60)
GVAX Pancreatic Neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	B (60)
Lenvatinib Pancreatic Neoplasm	Medical College of Wisconsin	P2	B (60)
Marcaine Pancreatic Neoplasm	Masonic Cancer Center, University of Minnesota	P2	B (60)
Nivestim Pancreatic Neoplasm	General Oncology, Inc.	P3	B (60)
Panitumumab Pancreatic Neoplasm	Cancer Trials Ireland	P2	B (60)
Pembrolizumab Pancreatic Neoplasm	Cambridge University Hospitals NHS Foundation Trust	P4	B (60)
Qingyihuaji Optimized Formula Pancreatic Neoplasm	Fudan University	P3	B (60)
Gvax Pancreas Vaccine Pancreatic Neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	B (59)
Trastuzumab Pancreatic Neoplasm	Cancer Research UK	P2/3	B (59)
Adriamycin Pancreatic Neoplasm	Northwell Health	P2	B (58)
Carboplatin Pancreatic Neoplasm	Jinling Hospital, China	P2	B (58)
Dalteparin Pancreatic Neoplasm	Helsinki University Central Hospital	P4	B (58)
Fludarabine Pancreatic Neoplasm	National Cancer Institute (NCI)	P2	B (58)
Ivonescimab Pancreatic Neoplasm	Akeso	P3	B (58)
Meperidine Pancreatic Neoplasm	National University of Malaysia	P4	B (58)
Midazolam Pancreatic Neoplasm	National University of Malaysia	P4	B (58)
Sorafenib Pancreatic Neoplasm	Medical College of Wisconsin	P3	B (58)
Toripalimab Pancreatic Neoplasm	Ruijin Hospital	P2	B (58)
Vandazole Pancreatic Neoplasm	Icahn School of Medicine at Mount Sinai	P4	B (58)
Dostarlimab Pancreatic Neoplasm	Hopital Foch	P2	B (57)
Enoxaparin Pancreatic Neoplasm	Helsinki University Central Hospital	P4	B (57)
Etoposide Pancreatic Neoplasm	Jinling Hospital, China	P2	B (57)
Ipilimumab Pancreatic Neoplasm	Shandong Cancer Hospital and Institute	P2	B (57)
Lanreotide Pancreatic Neoplasm	SWOG Cancer Research Network	P3	B (57)
Penpulimab Pancreatic Neoplasm	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P2	B (57)
Ropivacaine Pancreatic Neoplasm	Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor	P4	B (57)
Tegodor Pancreatic Neoplasm	Ruijin Hospital	P2	B (57)
Ciprofloxacin Pancreatic Neoplasm	Icahn School of Medicine at Mount Sinai	P4	B (56)
Disitamab Vedotin Pancreatic Neoplasm	Memorial Sloan Kettering Cancer Center	P2	B (56)
Durvalumab Pancreatic Neoplasm	AHS Cancer Control Alberta	P2	B (56)
Hydroxychloroquine Pancreatic Neoplasm	Cancer Trials Ireland	P2	B (56)
Pancrelipase Pancreatic Neoplasm	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	P4	B (56)
Pasireotide Pancreatic Neoplasm	Helsinki University Central Hospital	P4	B (56)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Pancreatic Neoplasm	AHS Cancer Control Alberta	P2	CCC (55)

Showing 1 to 50 of 377 assets

PreviousPage 1 of 8Next